BiomX Inc. has announced that it has entered into a securities purchase agreement with investors for expected aggregate gross proceeds of approximately $12 million. The financing will support the completion of the Phase 2b clinical study of BX004 for the treatment of people with CF with chronic pulmonary infections caused by Pseudomonas aeruginosa, as well as the analysis of real-world evidence. The Company expects to report topline results from the Phase 2b study in Q1 2026.
Company Information
Company
BiomX
Location
22 EINSTEIN ST., FLOOR 4
Ness Ziona, Central District, Israel
About
BiomX is focused on acquiring and developing technologies that identify, analyze, protect against, and support faster responses to physical threats. The company operates as a subsidiary of BiomX Inc. and is involved in enhancing security systems. With a strategic focus on defense and security, BiomX aims to integrate advanced technologies into operational environments. It addresses critical infrastructure needs across various sectors.
Ness ZionaBiotechnologyHealthcareHealth CareTherapeutics